Key facts
- This page summarizes GILEAD SCIENCES, INC.'s Form 4 filing for Arcus Biosciences, Inc. (RCUS).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 20 Feb 2025, 19:42.
GILEAD SCIENCES, INC. - 18 Feb 2025 Form 4 Insider Report for Arcus Biosciences, Inc. (RCUS)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- RCUS
- Reported as of
- 18 Feb 2025
- Net transaction value
- +$14,999,996
- SEC form
- 4
- Accepted by SEC
- 20 Feb 2025, 19:42:29 UTC
- Prior SEC filing
- 23 Dec 2024
- Next SEC filing
- 06 Jun 2025
- Source filing
- View source filing
- Reporting owner signature
- Gilead Sciences, Inc. By: /s/ Andrew D. Dickinson
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
GILEAD SCIENCES, INC. filed Form 4 for Arcus Biosciences, Inc. (RCUS) on 20 Feb 2025.
Change
- Previous filing in this sequence was filed on 23 Dec 2024.
- Current net transaction value: +$14,999,996.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
RCUS
transaction
Common Stock
Purchase
- Transaction value
- $14,999,996
- Shares
- +1,363,636
- Change %
- +4.5%
- Price
- $11.00
- Shares after
- 31,424,760
- Date
- 18 Feb 2025
- Ownership
- Direct
* marks a reported price that did not pass the local price check.